Replies to post #30230 on Humanigen Inc (fka HGENQ)

[AC11]

My take and thoughts/conjecture:

A lot of what you say is correct but when it comes down to it, they are different trials asking different questions despite their significant similarities. Different endpoints. Different interventions. You can’t just extrapolate one to the other. I don’t think this is a concern. If an EUA is given for lenz, it will probably be very narrow and specifically for the study inclusion criteria and interventions of LIVE-AIR and (my guess) independent of remdesivir use or not. Lenz plus remdesivir is a different clinical question not answered by LIVE-AIR. Yes data was provided in LIVE-AIR about the combo but again, different trial and different design. ACTIV will continue to collect that data but again, different clinical question being answered by a different measurement outcome.